Improved Renal Outcomes in Kidney Transplant Recipients with Early Denovo DSAs on Belatacept versus Calcineurin Inhibitor-Based Immunosuppression

被引：0
|
作者：
Gattis, S. [1 ]
Agrawal, M. [2 ]
Pang, S. [2 ]
Basu, A. [1 ]
机构：
[1] Emory Healthcare, Atlanta, GA USA
[2] Emory Univ Hosp, 1364 Clifton Rd NE, Atlanta, GA 30322 USA
来源：
AMERICAN JOURNAL OF TRANSPLANTATION | 2023年 / 23卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
A194
引用
下载
收藏
页码：S698 / S698
页数：1
相关论文
共 50 条
  • [1] Conversion from calcineurin inhibitor-based immunosuppression to mammalian target of rapamycin inhibitors or belatacept in renal transplant recipients
    Mulgaonkar, Shamkant
    Kaufman, Dixon B.
    CLINICAL TRANSPLANTATION, 2014, 28 (11) : 1209 - 1224
  • [2] Outcomes of Conversion From Calcineurin Inhibitor to Belatacept-based Immunosuppression in HLA-sensitized Kidney Transplant Recipients
    Sethi, Supreet
    Najjar, Reiad
    Peng, Alice
    Choi, Jua
    Lim, Kathlyn
    Vo, Ashley
    Jordan, Stanley C.
    Huang, Edmund
    TRANSPLANTATION, 2020, 104 (07) : 1500 - 1507
  • [3] Three-Year Outcomes in Kidney Transplant Recipients Switched From Calcineurin Inhibitor-Based Regimens to Belatacept as a Rescue Therapy
    Morel, Antoine
    Hoisnard, Lea
    Dudreuilh, Caroline
    Moktefi, Anissa
    Kheav, David
    Pimentel, Ana
    Sakhi, Hamza
    Mokrani, David
    Attias, Philippe
    El Sakhawi, Karim
    Champy, Cecile Maud
    Remy, Philippe
    Sbidian, Emilie
    Grimbert, Philippe
    Matignon, Marie
    TRANSPLANT INTERNATIONAL, 2022, 35
  • [4] Clinical Outcomes of Conversion from Calcineurin Inhibitor to Belatacept-Based Immunosuppression in Highly Sensitized Kidney Transplant Recipients.
    Sethi, S.
    Choi, J.
    Vo, A.
    Peng, A.
    Lim, K.
    Najjar, R.
    Jordan, S.
    Huang, E.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 291 - 292
  • [5] DOSING RATIONALE OF BELATACEPT IN PEDIATRIC RENAL TRANSPLANT RECIPIENTS SWITCHING FROM CALCINEURIN INHIBITOR-BASED REGIMEN.
    Lee, S.
    Zhou, Z.
    Roy, A.
    Jones-Burton, C.
    Harler, M.
    Shen, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 : S75 - S75
  • [6] Outcomes in Kidney Transplant Recipients with Pretransplant Uncontrolled Diabetes on Belatacept versus Tacrolimus Based Immunosuppression
    Durham, R.
    Basu, A.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2023, 23 (06) : S993 - S993
  • [7] COMPARISON OF CLINICAL OUTCOMES FOR BELATACEPT VERSUS CALCINEURIN INHIBITOR AMONG DCD AND/OR HIGH KDPI KIDNEY TRANSPLANT RECIPIENTS
    Rizvi, Asim
    Nguyen, Thang
    Zill, Allison
    Kueht, Michael
    Rawala, Muhammad
    Gamilla-Crudo, Ann
    Hussain, Syed
    Mujtaba, Muhammad
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2022, 79 (04) : S122 - S123
  • [8] Belatacept-based immunosuppression: A calcineurin inhibitor-sparing regimen in heart transplant recipients
    Launay, Manon
    Guitard, Joelle
    Dorent, Richard
    Prevot, Yoann
    Prion, Florent
    Beaumont, Laurence
    Kably, Benjamin
    Lecuyer, Lucien
    Billaud, Eliane M.
    Guillemain, Romain
    AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 (02) : 553 - 563
  • [9] Microvascular inflammation is a risk factor in kidney transplant recipients with very late conversion from calcineurin inhibitor-based regimens to belatacept
    Mira Choi
    Friederike Bachmann
    Kaiyin Wu
    Nils Lachmann
    Danilo Schmidt
    Susanne Brakemeier
    Michael Duerr
    Andreas Kahl
    Kai-Uwe Eckardt
    Klemens Budde
    Peter Nickel
    BMC Nephrology, 21
  • [10] MICROVASCULAR INFLAMMATION IS A RISK FACTOR IN KIDNEY TRANSPLANT RECIPIENTS WITH VERY LATE CONVERSION FROM CALCINEURIN INHIBITOR-BASED REGIMENS TO BELATACEPT
    Choi, M.
    Bachmann, F.
    Kahl, A.
    Schmidt, D.
    Budde, K.
    Eckardt, K. -U.
    Brakemeier, S.
    Duerr, M.
    Wu, K.
    Lachmann, N.
    Nickel, P.
    TRANSPLANT INTERNATIONAL, 2020, 33 : 11 - 11
12345